XXII — 22nd Century Group, Inc.

Summary of 22nd Century Group's Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Net Revenue: $4 million, a slight decrease from $4.1 million in Q2 2025.
• Cartons Sold: 517,000, down from 779,000 in the previous quarter.
• Gross Profit: Loss of $1.1 million, worsening from a $0.6 million loss in Q2 2025, attributed to lower sales volume and restructuring costs.
• Operating Expenses: $2.2 million, down from $2.3 million in Q2.
• Net Loss: Approximately $3.8 million, compared to a loss of $3.3 million in Q2.
• Adjusted EBITDA: Loss of $2.9 million, slightly worse than a $2.6 million loss in Q2.
• Cash Position: $4.8 million on hand, with an additional $9.5 million received from an insurance settlement post-quarter.
• Debt: The company is now debt-free after repaying its senior secured credit facility.

2. Strategic Updates and Business Highlights

• Business Transition: Shift from low-margin contract manufacturing operations to focus on higher-margin branded products, particularly Very Low Nicotine (VLN) offerings.
• Product Launches: New VLN and partner-branded products are now available in approximately 1,500 stores across 21 states.
• Market Positioning: The company aims to be a leader in the Tobacco Harm Reduction movement, advocating for low-nicotine products to align with FDA regulations.
• Technology Development: Plans to offer low-nicotine leaf to other market players and pursue licensing opportunities for their technology.
• Brand Expansion: Introduction of natural style cigarettes alongside VLN products to enhance market penetration and brand recognition.

3. Forward Guidance and Outlook

• Breakeven Target: The company aims to achieve EBITDA breakeven by Q2 2026, contingent on improving sales metrics.
• Sales Growth: Anticipates sequential improvement in sales and profitability as higher-margin products gain market traction.
• Distribution Goals: Plans to expand distribution to all 50 states and increase store count significantly in 2026.

4. Bad News, Challenges, or Points of Concern

• Declining Sales Volume: The drop in cartons sold reflects the ongoing transition away from lower-margin products, which may impact short-term revenue.
• Gross Profit Losses: Continued losses at the gross profit line indicate challenges in achieving profitability during the transition phase.
• Market Competition: The company faces competition from other tobacco and alternative product manufacturers, which may hinder market share growth.
• Regulatory Risks: While the company supports FDA's low nicotine mandate, opposition from other industry players could create a challenging regulatory environment.

5. Notable Q&A Insights

• Cash Utilization: Management indicated that the cash on hand will support growth initiatives, including expanding VLN distribution and some R&D efforts.
• Warrants and Share Structure: Approximately 7 million shares outstanding, with a fully diluted basis of 23.7 million shares.
• Executive Agreements: New employment agreements for executives were established to align with the company's growth strategy.
• Commitment to Breakeven: Management reaffirmed their target for EBITDA breakeven by Q2 2026, despite current sales metrics not yet reflecting this goal.

Overall, 22nd Century Group is in a transitional phase, focusing on higher-margin products while navigating challenges related to sales volume and market competition. The company is optimistic about its future growth potential and commitment to the Tobacco Harm Reduction movement.